Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex

Next Previous
Trial Profile

An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Cancer pain; Diabetic neuropathies; Multiple sclerosis; Muscle spasticity; Neuropathic pain
  • Focus Adverse reactions
  • Sponsors Jazz Pharmaceuticals Inc

Most Recent Events

  • 28 Oct 2022 Results of post hoc analysis assessing the long-term dosage of nabiximols, to evaluate real-world dosing and to investigate the association between dosage and premature study discontinuation in MS-related spasticity from GWMS1137 (n=62) and GWSR10128 (N=765) studies, presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
  • 10 Oct 2017 Status changed from recruiting to completed.
  • 10 Oct 2015 Final results of patients from the United Kingdom (n=941) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top